. 2004 Jan;10(1):109–116. doi: 10.3201/eid1001.020714

Table 3. Incidence density (ID)^a and standard deviation (SD) of medically diagnosed infectious diseases, and selected crude and adjusted rate ratios (RR), among human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, visits 2 and 3.

Diagnosis	HTLV seronegative  (N = 799)	HTLV-I (N = 152)			HTLV-II (N = 387)
Diagnosis	ID (SD)	ID (SD)	RR^b	Adj. RR (95% CI)^c	ID (SD)	RR^b	Adj. RR (95% CI)^c
Pneumonia	0.08 (0.37)	0.11 (0.47)	1.49	1.33 (0.66 to 2.66)	0.21 (0.96)	2.82	2.65 (1.67 to 4.21)
Acute Bronchitis	0.59 (1.78)	0.82 (2.25)	1.38	1.33 (0.84 to 2.12)	1.10 (2.75)	1.83	1.53 (1.10 to 2.14)
Bladder or Kidney infection	0.63 (2.04)	1.75 (4.61)	2.73	2.32 (1.50 to 3.59)	1.25 (3.48)	1.94	1.94 (1.40 to 2.68)

^aDefined as the mean of the total number of infectious disease diagnoses divided by the number of participants (with or without the infection) in each group at baseline. The period of observation was 4.4 years (HTLV-I), 4.3 years (HTLV-II), and 4.4 years (HTLV seronegative), and each participant may have multiple diagnoses of each condition.^bUnadjusted. ^cAdjusted. Adjusted models included age, gender, race/ethnicity and duration of follow-up for all infections, and injection drug use (for pneumonia), smoking (for acute bronchitis), and community versus autologous blood donation (for bladder/kidney infection).

Table 3. Incidence density (ID)a and standard deviation (SD) of medically diagnosed infectious diseases, and selected crude and adjusted rate ratios (RR), among human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, visits 2 and 3.

Table 3. Incidence density (ID)^a and standard deviation (SD) of medically diagnosed infectious diseases, and selected crude and adjusted rate ratios (RR), among human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, visits 2 and 3.